Our current development programs are focused on vaccines against COVID-19; Hemorrhagic Fever viruses such as Ebola (Zaire, Sudan), Lassa and Marburg; Malaria and Zika virus; and, Human Immunodeficiency Virus (HIV). We have also initiated programs to develop an immunotherapy against tumor associated antigen MUC1 that is associated with metastatic progression of many cancer types including breast, ovarian, gastric, liver, pancreas, renal and  lymph nodes and an immunotherapy to treat human papilloma virus (HPV)-induced cancers.